Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWatches Switz Regulatory News (WOSG)

Share Price Information for Watches Switz (WOSG)

Share Price is delayed by 15 minutes
Get Live Data
706.50    -11.00 (-1.53%)
Bid:
702.50
Ask:
704.00
Spread: 1.50 (0.214%)
Market Cap: £1.63b
WOSG Live PriceLast checked at - London Stock Exchange

Intraday Watches Switz Share Chart

Stabilisation Notice

30 May 2019 07:00

RNS Number : 5385A
Goldman Sachs International
30 May 2019
 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Watches of Switzerland Group Limited

Stabilisation Notice

30 May 2019

Goldman Sachs International hereby gives notice that the entity undertaking stabilisation (the "Stabilisation Manager" named below and its affiliates) may stabilise the offer of the following securities in accordance with Regulation (EU) No 596/2014 (Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052. Stabilisation transactions aim at supporting the market price of the Securities during the Stabilisation Period. Stabilisation may not necessarily occur and it may cease at any time.

The securities:

Issuer:

Watches of Switzerland Group Limited (to be re-registered as a public limited company and re-named as Watches of Switzerland Group PLC)

Securities:

Ordinary registered shares ("ORDs" or "Ordinary Shares") of the Issuer (ISIN: GB00BJDQQ870)

Offering size:

81,481,481 Ordinary Shares (excluding the over-allotment option)

Offer Price:

GBP 2.70

Stabilisation:

Stabilisation Manager (and central point within the meaning of Commission Delegated Regulation (EU) 2016/1052):

Goldman Sachs International, Peterborough Court, 133 Fleet Street, London EC4A 2BB

Contact: Luke Hicks; telephone: +44 (0)20 7552 1169

Beginning of the Stabilisation Period:

30 May 2019

Stabilisation Period to end no later than:

28 June 2019

Trading venue where stabilisation may be undertaken:

London Stock Exchange ("LSE"), BATS, Chi-X

Over-allotment & Greenshoe Option:

Terms:

In connection with the offering (the "Offer"), the Stabilisation Manager, or any of its agents, may (but will be under no obligation to), to the extent permitted by applicable law, over-allot Ordinary Shares sold in the Offer (the "Offer Shares") or effect other stabilisation transactions with a view to supporting the market price of the Offer Shares at a level higher than that which might otherwise prevail in the open market pursuant to an over-allotment option granted to it in connection with the Offer (the "Over-allotment Option"). The Stabilisation Manager is not required to enter into such transactions and such transactions may be effected on any securities market, over-the-counter market, stock exchange or otherwise and may be undertaken at any time during the period commencing on the date of the commencement of conditional dealings in the Offer Shares on the LSE and ending no later than 30 calendar days thereafter. There will be no obligation on the Stabilisation Manager or any of its agents to effect stabilising transactions and there is no assurance that stabilising transactions will be undertaken. Such stabilisation, if commenced, may be discontinued at any time without prior notice. In no event will measures be taken to stabilise the market price of the Offer Shares above £2.70 per Offer Share. Except as required by law or regulation, neither the Stabilisation Manager nor any of its agents intends to disclose the extent of any over-allotments made and/or stabilisation transactions conducted in relation to the Offer.

In connection with the Offer, the Stabilisation Manager may, for stabilisation purposes, over-allot Offer Shares up to a maximum of 10% of the total number of Offer Shares comprised in the Offer.

The Over-allotment Option is exercisable in whole or in part, upon notice by the Stabilisation Manager, at any time on or before the 30th calendar day after the commencement of conditional dealings in the Offer Shares on the LSE. Any Over-allotment Shares made available pursuant to the Over-allotment Option will rank pari passu in all respects with all other Ordinary Shares, including for all dividends and other distributions declared, made or paid on the Ordinary Shares, will be purchased on the same terms and conditions as the Offer Shares being issued or sold in the Offer and will form a single class for all purposes with the other Ordinary Shares.

Number of shares covered by Over-allotment Option:

8,148,148 Ordinary Shares

Duration:

This option may be executed at any time during the Stabilisation Period.

 

 

 

Disclaimer

 

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information only and does not constitute an offer or invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities or investment advice in any jurisdiction in which such an offer or solicitation is unlawful, including without limitation, the United States, Australia, Canada, or Japan. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions.

 

This announcement and the information contained herein, is not an offer of securities for sale in, and is not for transmission to or publication, distribution or release, directly or indirectly, in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"). The securities being offered have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any applicable securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, transferred or delivered, directly or indirectly, in the United States unless registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, such registration requirements and in accordance with any applicable securities laws of any state or other jurisdiction of the United States. No public offering of the securities discussed herein is being made in the United States.

 

This announcement is directed only at: (A) persons in member states of the European Economic Area (the "EEA") who are "qualified investors" within the meaning of Article 2(1)(e) of the EU Prospectus Directive (Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the relevant member state of the EEA) and includes any relevant implementing measure in each relevant member state of the EEA) (the "Qualified Investors"); (B) in the United Kingdom, Qualified Investors who are persons who (i) have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"); or (ii) are high net worth entities falling within Article 49 of the Order; or (iii) are persons to whom it may otherwise be lawfully communicated. If you are not a person to whom this announcement is directed as set out in (A) and (B) above, you will not be eligible to participate in the offering, and you should not act upon, or rely on, this announcement.

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STAPGURWAUPBPGB
Date   Source Headline
25th Aug 20237:45 amRNSResponse to acquisition of Rolex SA of Bucherer SA
10th Aug 20237:00 amRNSQ1 FY24 Trading Update
4th Aug 20234:24 pmRNSHolding(s) in Company
1st Aug 20237:00 amRNSNotice of Q1 FY24 Trading Update
31st Jul 20232:23 pmRNSAnnual Financial Report
21st Jul 202310:56 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSFY23 Results
14th Jun 20232:13 pmRNSHolding(s) in Company
17th May 20237:00 amRNSQ4 FY23 Trading Update
12th May 20232:30 pmRNSDirector Declaration
3rd May 20237:00 amRNSDirectorate Change
25th Apr 20238:22 amRNSDirector Declaration
18th Apr 20237:00 amRNSNotice of Q4 FY23 Trading Update
13th Feb 20232:16 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSQ3 FY23 Trading Update
17th Jan 20237:00 amRNSNotice of Q3 FY23 Trading Update
14th Dec 20227:00 amRNSH1 FY23 Results
8th Dec 20224:47 pmRNSHolding(s) in Company - Replacement
8th Dec 202211:04 amRNSHolding(s) in Company
15th Nov 20223:47 pmRNSHolding(s) in Company
9th Nov 20227:00 amRNSQ2 FY23 Trading Update
20th Oct 20227:00 amRNSNotice of Q2 Trading Update
6th Oct 20221:55 pmRNSHolding(s) in Company
2nd Sep 20222:46 pmRNSHolding(s) in Company
2nd Sep 20227:00 amRNSAppointment of Corporate Broker
1st Sep 20225:23 pmRNSResult of AGM
1st Sep 202212:20 pmRNSDirector/PDMR Shareholding
18th Aug 202211:33 amRNSHolding(s) in Company
16th Aug 20227:00 amRNSQ1 FY23 Trading Update
4th Aug 20227:00 amRNSNotice of Q1 FY23 Trading Update
27th Jul 20221:12 pmRNSAnnual Financial Report
15th Jul 20222:14 pmRNSDirector/PDMR Shareholding
15th Jul 20222:09 pmRNSDirector/PDMR Shareholding
12th Jul 20224:46 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSFY22 Results
6th Jul 202212:17 pmRNSDirectorate Change
9th Jun 20222:17 pmRNSBlock Listing Six Monthly Return
18th May 20227:00 amRNSWatches of Switzerland Q4 FY22 Trading
10th May 202210:00 amRNSHolding(s) in Company
9th May 202211:30 amRNSUpdated notice for Q4 FY22 Trading Update
3rd May 20223:10 pmRNSDirectorate Change
11th Apr 20227:00 amRNSDirectorate Change
7th Apr 20227:00 amRNSNotice of Q4 FY22 Trading Update
29th Mar 20221:42 pmRNSDirector/PDMR Shareholding
28th Mar 20223:17 pmRNSDirector/PDMR Shareholding
28th Mar 202210:48 amRNSDirector/PDMR Shareholding
8th Mar 20227:00 amRNSStatement on Russian invasion of Ukraine
28th Feb 202210:44 amRNSHolding(s) in Company
17th Feb 202212:49 pmRNSDirector/PDMR Shareholding
10th Feb 20227:00 amRNSQ3 FY22 Trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.